Evidence map›Paper›PMID 27766382›Full record

ArticleDer Pathologe2016

[Cervical cancer : Update on morphology].

L-C Horn, C E Brambs, R Handzel, S Lax, I Sändig, D Schmidt, K Schierle

Abstract read
PubMed Publisher
In one paragraph

Article in Der Pathologe, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

L-C HornAbteilung Mamma-, Gynäko- und Perinatalpathologie, Institut für Pathologie, Universitätsklinikum Leipzig AöR, Liebigstraße 26, 04103, Leipzig, Deutschland. hornl@medizin.uni-leipzig.de.
C E BrambsFrauenklinik des Klinikums rechts der Isar, Technische Universität München, München, Deutschland.
R HandzelUniversitätsfrauenklinik Leipzig (Triersches Institut) im Zentrum für Frauen- und Kindermedizin, Universitätsklinikum Leipzig AöR, Leipzig, Deutschland.
S LaxInstitut für Pathologie, Landeskrankenhaus Graz Süd-West, Graz, Österreich.
I SändigAbteilung Mamma-, Gynäko- und Perinatalpathologie, Institut für Pathologie, Universitätsklinikum Leipzig AöR, Liebigstraße 26, 04103, Leipzig, Deutschland.
D SchmidtInstitut für Pathologie, Viersen, Deutschland.
K SchierleAbteilung Mamma-, Gynäko- und Perinatalpathologie, Institut für Pathologie, Universitätsklinikum Leipzig AöR, Liebigstraße 26, 04103, Leipzig, Deutschland.
University Hospital Leipzig · DEKlinikum rechts der Isar · DELandeskrankenhaus Feldkirch · ATLVR-Klinik für Orthopädie Viersen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization (WHO) classification from 2014 differentiates between different subtypes of mucinous adenocarcinoma of the uterine cervix. A gastric subtype was recently described that showed no association with high-risk human papillomavirus (HPV) infections, has a poor prognosis, is mainly diagnosed in women of Asian origin and can occur in patients with Peutz-Jeghers syndrome. Although no clear grading system has been recommended in the WHO classification, it is likely that grading of adenocarcinomas of the uterine cervix will partly be based on the different patterns of invasion. Deep stromal infiltration of macroinvasive carcinomas is defined as an infiltration of >66 % of the cervical stroma. In the near future a maximum tumor size of 2 cm could act as a discriminator for planning of less radical surgery. Parameters of the histopathological report that are relevant for the prognostic assessment as well as the choice of adjuvant treatment and function as quality indicators during certification are described. The histological type of an adenocarcinoma alone is of no predictive or prognostic relevance for patients undergoing primary surgical treatment, neoadjuvant chemotherapy, combined chemo-radiotherapy or treatment with angiogenesis inhibitors. Currently, molecular parameters and biomarkers are of no relevance.

Indexed as

World Health OrganizationAdenocarcinoma, MucinousBiomarkers, TumorCervix UteriCombined Modality TherapyFemaleHuman papillomavirus 16HumansNeoplasm GradingNeoplasm InvasivenessPapillomavirus InfectionsPathology, MolecularPrognosisQuality Indicators, Health CareUterine Cervical NeoplasmsUterine NeoplasmsBiomarkers, TumorAdenocarcinomaBiomarkersGradingMolecular pathologyQuality indicators

Identifiers

PMID27766382
OpenAlexW2537462256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.